Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAIC + PD-1 Antibody vs HAIC + Sorafenib for Advanced HCC
NCT03780634Phase 2Withdrawn
- Sponsor
- Sun Yat-sen University
- Start
- Apr 2019
- Primary completion
- Dec 2020
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in hepatocellular carcinoma (HCC) (2 arms), sponsored by Sun Yat-sen University. Primary endpoint: Progression Free Survival at 12 months. Planned start Apr 2019; status: withdrawn.
02
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03780634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03780634.